Tandem Diabetes Care (NSDQ:TNDM) announced today that it appointed Dr. Jordan Pinsker as its VP & medical director. The San Diego-based insulin delivery technology developer’s appointment of Pinsker will be made effective on April 26, 2021, according to a news release. Pinsker joins Tandem from Sansum Diabetes Research Institute in Santa Barbara, Calif., where he served […]
Tandem Diabetes Care
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%. The San Diego-based insulin delivery and […]
Canada approves Tandem Diabetes Caree’s advanced hybrid closed-loop insulin pump
Tandem Diabetes Care (NSDQ:TNDM) announced today that Health Canada has approved its t:slim X2 insulin pump with Control-IQ technology. The news comes nearly a year after the U.S. launch of the t:slim X2 with Control-IQ. All in-warranty t:slim X2 pump users in Canada will be able to add Control-IQ technology to their existing pump via a […]
Tandem Diabetes slides after hours on mixed bag Q3
Tandem Diabetes Care (NSDQ:TNDM) shares took a hit after hours today on third-quarter results that were mixed compared to the consensus forecast. The San Diego-based insulin delivery and diabetes technology company posted losses of -$9.4 million, or -15¢ per share, on sales of $123.6 million for the three months ended Sept.30, 2020, for a bottom-line slide […]
Tandem Diabetes posts $27m Q2 loss, reinstates earlier guidance
Tandem Diabetes Care (NSDQ:TNDM) posted Street-beating second-quarter sales and missed badly on earnings, but reinstated its earlier full-year 2020 guidance. The San Diego-based company — maker of insulin pumps and other diabetes management devices — reported a loss of -$27.1 million or -0.45¢ per share, on sales of $109.2 million for the three months ended June […]
Medtronic, Tandem Diabetes Care bury the hatchet on potential IP disputes
Two major insulin pump makers — Medtronic (NYSE:MDT) and Tandem Diabetes Care (NSDQ:TNDM) — announced today that they’ve inked a non-exclusive patent cross-license agreement related to diabetes treatment tech. The companies said the agreement will allow them to focus on innovation while avoiding the distraction of potential legal disagreements. The deal could be but another example of […]
Abbott, Tandem seal deal to combine CGM, insulin delivery tech
Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott’s Freestyle Libre CGM with Tandem’s t:slim X2 pump to monitor glucose without fingersticks. The agreement covers the technical development of device integration […]
Tandem Diabetes Care acquires Sugarmate mobile app
Tandem Diabetes Care (NSDQ:TNDM) said today that it has purchased Sugarmate — as mobile app that helps people better manage their diabetes. Financial terms of the deal were not disclosed. Nearly 30,000 people relying on insulin pumps or multiple daily injections presently use the Sugarmate app. Sugarmate cofounder Josh Juster will join Tandem as a VP […]
Tandem Diabetes Care wins expanded FDA indication for insulin pump
Tandem Diabetes Care (NSDQ:TNDM) announced today that it won an expanded pediatric indication from the FDA for its t:slim X2 insulin pump. The t:slim X2 with Control-IQ technology won FDA clearance for controlling Type 1 diabetes in December, which was followed by a commercial launch in the U.S. the next month. Tandem touts t:slim X2 with […]